Biotech Stocks

Here Are My Top 3 Biotech Stocks

By Genia Turanova There’s nothing like cash to show how successful a company has been. When a fledgling enterprise first turns cash-flow positive …

Spectrum Pharmaceuticals’ (SPPI) Encouraging Clinical Update in NSCLC Gets the Bulls in a Buying Frenzy

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) just riled up Wall Street today with enticing Phase 2 study results in non-small cell lung cancer (NSCLC), sending …

What’s in Store for Incyte Corporation (INCY) After “Big Time” Clinical Miss? Reni Benjamin Chimes In

Raymond James’ Reni Benjamin may scale back his expectations on INCY, but still bets on 24% in return potential for shares.

Why This Analyst No Longer Makes a Bearish Call on Valeant Pharmaceuticals (VRX)

Mizuho’s Irina Rivkind Koffler has gotten more upbeat on the VRX name, but her raised expectations watch for 6% in loss potential for the stock.

Do Scpharmaceuticals (SCPH) and Rigel Pharmaceuticals (RIGL) Have Winning Catalysts Ahead? Analysts Say Yes

With SCPH standing before the FDA this summer and RIGL in less than two weeks’ time, two bulls are placing their bets behind these drug makers.

Eleven Biotherapeutics Inc’s (EBIO) Positive Phase 3 Trial Data in NMIBC Sends Investors on a Buying Frenzy

Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares are jumping up like wildfire today on back of an encouraging Phase 3 trial data preview in bladder …

Valeant Pharmaceuticals Intl Inc (VRX) Subsidary Salix Wins Over Support of IBS Awareness Month Founders for New National Campaign

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wholly owned subsidiary Salix is fostering a new two-way conversation between health care providers and irritable bowel syndrome …

Omeros Corporation (OMER): Omidria Can Now Stage a Comeback to Former Sales Gains, Says Jason McCarthy

With new hope for a two-year reimbursement extension for Omidria, Jason McCarthy now bets on 58% in return potential for the stock.

AbbVie Inc (ABBV) Has More Than Just a Terrible Setback for Rova-T to Confront; Bear Warns Further Downside Risk Lies Ahead

Alex Arfaei notes he continues to be the “lone bear” on this biotech player- especially after lead pipeline asset Rova-T is no longer looking at quick approval.